| 英文名稱 | Lixisenatide |
|---|---|
| 中文名稱 | 利西拉來;利西拉肽 |
| CAS號(hào) | 320367-13-3 |
| 分子式 | C215H347N61O65S |
| 分子量 | 4,858.49 |
| MDL | MFCD13194768 |
| 外觀 | White to pink powder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| 英文名稱 | Lixisenatide |
|---|---|
| 中文名稱 | 利西拉來;利西拉肽 |
| CAS號(hào) | 320367-13-3 |
| 分子式 | C215H347N61O65S |
| 分子量 | 4,858.49 |
| MDL | MFCD13194768 |
| 外觀 | White to pink powder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels.
PMID: 35498599 PMCID: PMC9050383 DOI: 10.1039/c9ra09959j
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats [J].
PMID: 33065146 DOI: 10.1016/j.lfs.2020.118592
PMID: 31336333 DOI: 10.1016/j.intimp.2019.105732